2008: ACR Business Meeting and Late-Breaking Abstracts
Search or Browse by Day

ACR Business Meeting and Late-Breaking Abstracts

Tuesday, October 28, 2008
L11
A Phase 3 Randomized, Controlled, Multicenter, Double-Blind Trial (RCT) Comparing Efficacy and Safety of Daily Febuxostat (FEB) and Allopurinol (ALLO) in Subjects with Gout
L12
Efficacy and Safety of Rituximab in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (SLE): Results from the Randomized, Double-blind Phase II/IIIStudy EXPLORER
L13
The Oral Jak Inhibitor CP-690,550 (CP) in Combination with Methotrexate (MTX) is Efficacious, Safe and Well Tolerated in Patients with Active Rheumatoid Arthiritis (RA) with an Inadequate Response to Methotrexate Alone
L14
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: The LITHE Study
L15
The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study
L16
A 24 Week RDB Multicentric Trial to Demonstrate Equivalence between Individual Drugs for Symptomatic Treatment of OA Knees: Ayurvedic (Indian Asian) , Glucosamine and Celecoxib
See more of: Late Breaking Abstract ACR Concurrent Abstract Session
<< Previous Session Level | Next Session Level >>